Maybe he would have had that classic partner if the LP002 study was not delayed. Who knows. He got a great CLIA partner no matter how it is set up. ICON is way better than a BP to penetrate the RUO market and that is first. So chill out. The study data will likely bring a commercialization partner but the important first step is ICON and they have that nailed down. Technically they could wait on a BP partner and watch RUO revenue come in. When that happens the BP will have to pay more. So, you will get a better deal. I am quite sure that would make you happy.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links